News | August 22, 2013

Real-time Assessment of Tumor Response Presentation Wins Innovation Competition

Award goes to Dr. Kai Chen at the 2013 SNMMI meeting

August 22, 2013 — Molecular Targeting Technologies Inc. (MTTI) announced Dr. Kai Chen of the University of Southern California was awarded the 2013 Center for Molecular Imaging Innovation and Translation (CMIIT) Young Investigator Award during the annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in Vancouver, Canada. Chen presented results from his study entitled: “Synthesis and evaluation of a novel bis (zinc(II)-dipicolyamine) derivative for dual-modality PET/NIRF (positron emission tomography/near-infrared flourescence) imaging of phosphatidylserine exposure.”

This real-time assessment probe can be used to monitor tumor response in as early as one day to evaluate treatment efficacy and intervene early in treatment modification. Non-invasive imaging of drug response has a significant clinical impact and can be broadly useful for monitoring numerous conditions, including cancer, cardiovascular diseases, neurology and renal diseases.

Chen, assistant professor of the department of radiology at USC said, “Novel tools to assist in the non-invasive, real-time assessment of tumor response to anti-cancer treatment are urgently needed. Our current preclinical results could lead to a robust imaging agent, offering synergistic advantages, not only to allow comprehensive collection of cell death information, but also to facilitate clinical applications of image-guided surgery.”

For more information: mic.usc.edu, www.mtarget.com

Related Content

Radiography Education Enrollment Shows Marginal Rise in 2017
News | Business | February 15, 2018
Directors of radiography educational programs report the number of enrolled students increased slightly in 2017, while...
Patients Lack Information About Imaging Exams
News | Patient Engagement | February 14, 2018
Patients and their caregivers desire information about upcoming imaging examinations, but many are not getting it,...
A Tc99m SPECT cardiac exam showing myocardial perfusion in the heart.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 08, 2018 | Dave Fornell
February 8, 2018 — The U.S.
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
Small-Cell Lung Cancer Patients Face Barriers to Standard-of-Care Treatment
News | Lung Cancer | January 29, 2018
Despite decades of clinical research establishing chemotherapy with thoracic radiation as the standard-of-care for the...
Advaxis Immunotherapy Offers Potential Combo Treatment for Anal Cancer
News | Radiation Therapy | January 26, 2018
January 26, 2018 — Advaxis Inc.
Brain-scan guided emergency stroke treatment can save more lives
News | Neuro Imaging | January 25, 2018
January 25, 2018 – Advances in brain imagin...
PET Tracer Measures Damage From Multiple Sclerosis in Mouse Models
News | PET Imaging | January 24, 2018
January 24, 2018 — The loss or damage of myelin, a cellular sheath that surrounds and insulates nerves, is the hallma
Overlay Init